LXEO LEXEO THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, LEXEO THERAPEUTICS INC reported revenue of n/a, net income of −$25.9M and diluted EPS of −$0.30; for the fiscal year ended December 2025 revenue was n/a.
LXEO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$109M, net income −$100M (margin n/a), EPS −$1.86
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$106M, net income −$98.3M (margin n/a), EPS −$3.09
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$68.5M, net income −$66.4M (margin n/a), EPS −$12.40
- Fiscal year ended Dec 2022: revenue $654K, gross profit n/a, operating income −$60.5M, net income −$59.3M (margin -9063.8%), EPS −$36.36
LXEO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$25.9M, EPS −$0.30
- Quarter ended Mar 31, 2026: revenue n/a, net income −$20.2M, EPS −$0.25
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$21.0M, EPS $0.06
- Quarter ended Sep 30, 2025: revenue n/a, net income −$20.3M, EPS −$0.33
- Quarter ended Jun 30, 2025: revenue n/a, net income −$26.1M, EPS −$0.60
- Quarter ended Mar 31, 2025: revenue n/a, net income −$32.7M, EPS −$0.99
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$25.9M, EPS −$0.79
- Quarter ended Sep 30, 2024: revenue n/a, net income −$29.5M, EPS −$0.89
- Quarter ended Jun 30, 2024: revenue n/a, net income −$21.2M, EPS −$0.64
- Quarter ended Mar 31, 2024: revenue n/a, net income −$21.7M, EPS −$0.77
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$14.2M, EPS $19.84
- Quarter ended Sep 30, 2023: revenue n/a, net income −$20.1M, EPS −$12.36
- Quarter ended Jun 30, 2023: revenue n/a, net income −$13.4M, EPS −$8.30
- Quarter ended Mar 31, 2023: revenue n/a, net income −$18.7M, EPS −$11.58
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$14.6M, EPS n/a
- Quarter ended Sep 30, 2022: revenue $531K, net income −$17.1M, EPS −$10.38
- Quarter ended Jun 30, 2022: revenue n/a, net income −$15.1M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$12.5M, EPS n/a
LXEO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$98.6M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$81.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$59.5M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$54.6M, share buybacks n/a
LXEO balance sheet
- Jun 30, 2026: cash $92.8M, total assets $255M, total liabilities $19.8M, shareholders' equity $235M
- Mar 31, 2026: cash $71.8M, total assets $250M, total liabilities $18.9M, shareholders' equity $231M
- Dec 31, 2025: cash $63.0M, total assets $269M, total liabilities $22.0M, shareholders' equity $247M
- Sep 30, 2025: cash $41.0M, total assets $144M, total liabilities $23.0M, shareholders' equity $121M
- Jun 30, 2025: cash $35.5M, total assets $176M, total liabilities $37.9M, shareholders' equity $138M
- Mar 31, 2025: cash $28.9M, total assets $126M, total liabilities $37.6M, shareholders' equity $88.1M
- Dec 31, 2024: cash $35.0M, total assets $147M, total liabilities $30.1M, shareholders' equity $117M
- Sep 30, 2024: cash $157M, total assets $174M, total liabilities $34.5M, shareholders' equity $139M
Is LXEO profitable?
No. LEXEO THERAPEUTICS INC lost $87.3M over the last four quarters.
What is LXEO's EPS?
Diluted earnings per share over the last four quarters were −$0.82; −$0.30 in the latest quarter.